The Vygon Company strategy is clear, offer health professionals efficient and innovative single-use medical products adapted to their needs. With a high degree of quality and at a competitive price, we offer health-care professionals the best possible chances to treat and care for their patients in the most secured conditions. Innovation requires an understanding: our teams of marketing, R&D and sales representatives are working daily with our customers, listening to their needs, bringing creative and imaginative solutions to patient care. This high quality and responsive service compliments the proximity of production and research. That is why our plants are still located in Europe and in the United States of America. It’s our key to ensure constant high quality products.
This policy and strategy, requires long term commitment and a real involvement of all Vygon partners and managers. Stability and commitment of our shareholders enable us to invest in the long term, opting for quality and innovation instead of short term profitability, giving our teams and clients the warranty of a long term vision that everybody needs.
This willingness to act in the long term, some talk about Sustainable Development Strategy (SDS), allows Vygon to implement its leading vision of progress, integrating all stakeholders, in social, economic and environmental outcomes.
This strategy has proven to be effective. Since fifty years now, Vygon attracts more and more partners around the world. We are now present in more than one hundred countries in five continents. Our regular growth and profitability, warranty of our independence and our ability to innovate, testifies the quality of our products and our customer satisfaction.
France: Creation of the Vygon Company.
Pierre Simonet (on the right) has created Vygon in Ecouen, France. The Belgian engineer had always been motivated by the idea of progress and had in mind since the end of the second world war to focus his creative energies in Health Care. As soon as 1949, he created the first French Blood Bank. A change in legislation requiring a physician to head such an organisation put an end to this venture.
Then, he created the “Establishments Dubernard” with the aim of introducing a new material to replace glass which was a widespread use at that time but very unsafe and unpractical. This new material was plastic. Pierre Simonet sold the company in 1960 to Laboratoires Labaze and after a short stay at hospital, where he became aware of the difficulties involved in sterilising products, the complexity of the work performed by the nursing staff and the vast improvements needed for patient care, he had the idea of developping single-use medical devices. Vygon was born. Today, Stéphane Regnault, husband of the grand daughter of the creator, is continuing the family adventure.
Germany: Creation of this subsidiary in Aachen.
Thanks to that creation followed by the opening of a plant in 1973, Vygon starts building a group with an international dimension.
Belgium: Opening of the Dimequip plant in Frameries.
The plant is part of Vygon’s industrial cradle and produces high output manufacturing at competitive prices such as tracheal suction catheters and the Biovalve IV cannula, a major product for Vygon.
United Kingdom: Creation of a subsidiary.
Vygon UK is today the leading subsidiary of the group in terms of turnover.
Belgium: Creation of this subsidiary in Brussels.
Vygon Belgium has been in Brussels since 1998 and centralises all the commercial activity in Belgium, Holland and Luxembourg.
France : Opening of the SAP plant in St. Saulve near Valenciennes.
Since 1976, Vygon has been developping through the SAP plant disposable theatre products.
This plant is at the heart of Vygon’s new strategic stakes as it is involved in the development of custom packs among other things.
1978 / 1979
Creation of the Spanish, Dutch and Irish subsidiaries.
France : Opening of the SIPA plant in Avesnes sur Helpe, in the northern Pas-de-Calais region of France.
This plant has acquired extensive experience in manual or semi-automated production.
SIPA production includes respiratory products, wound drainage and the treatment of pain, such as epidural or spinal analgesia and nerve stimulation.
United states: Opening of Vygon Corporation, August 1, 1984, in East Rutherford, New Jersey.
Primary focus is neonatology, pediatrics and IV Therapy.
1994 / 1996
Portugal, India, Bulgaria: Creation of Portuguese and Indian subsidiaries.
Colombia: Opening of a Vygon plant at Barranquilla.
This represents a new opportunity for Vygon to widespread its activities in South America.
This plant develops and produces product lines which are particularly adapted to the South American market, this site is destined for major development in the short term.Surgical brushes, endotracheal tubes, scalp vein sets are some examples of products produced in Barranquilla.
Uruguay: Opening of the Uruguayan subsidiary.
Products of Neonatalogy are key products for the subsidiary.
Sweden: Opening of the subsidiary.
Since then, the growth of Vygon in Sweden has been strong thanks to two particular areas: Neonatalogy and respiratory medicine.
Italia: Opening of the Italian subsidiary.
In a very good position on the Italian market, its success is particularly good in the area of Regional analgesia. The Italian subsidiary is the fourth subsidiary of the group.
2003 / 2004
Czech Republic, Poland: Opening of the Czech and Polish subsidiaries.
Denmark: Opening of a subsidiary.
Dubaï: Opening of Vygon Middle East.
United states: Vygon purchases Advanced Medical Systems, a distributor, and Churchill Medical Products, a procedure kit, tray and accessories manufacturer.
This has considerably strengthened Vygon’s presence in the U.S. market. Primary focus is now neonatology, pediatrics, IV Therapy, oncology, ICUs’ emergency medicine in the hospital setting, as well as alternate care and homecare. Vygon Corporation has now re-located to Montgomeryville, Pennsylvania.
Norway: Opening of Vygon Norway.
Acquisition of Medwin, a French company specialized in enteral pumps.
– Opening of a subsidiary in Singapore– Acquisition of Perouse Medical
Finland: creation of a subsidiary
Acquisition of SEGAP.
Acquisition of Pilot.
Acquisition of Advanced Perfusion Diagnostics (APD).
Since its creation in 1962, continuous technological and market research, implementation of latest technology at all levels, dedication to customer satisfaction and high quality and reliability standards are the key factors in Vygon’s growth.
Vygon’s name has become synonymous with quality and reliability in the field of single-use medical and surgical products.
Vygon designs, manufactures and markets high-tech single-use medical devices for healthcare professionals. Vygon is a world leader within this industry, offering a wide range of products in a number of clinical specialties.
Organized in five business units:
- Critical Care
- Obstetrics Neonatology Enteral
- Intravascular Therapies
- Cardiovascular & Surgery
- Anesthesia & Emergency
Vygon combines local and international in-depth expertise and know-how in each individual field. With expertise right along the value chain, from product design to the delivery of training for medical personnel, Vygon provides health care professionals with effective and innovative products tailored to their needs and those of their patients, for optimum use and safety.
The company distributes over 205 million products a year in more than 120 countries through its network of 26 subsidiaries and 369 distributors. Conceived and designed by our engineers and technicians, Vygon products display the CE and/or FDA mark and are manufactured in the group’s eleven factories : 8 in Europe, 1 in the USA, 1 in Mauritius and 1 in Colombia.
A family company founded in 1962, Vygon is based in Ecouen, in France’s Greater Paris region, employing 2,350 staff worldwide. Turnover in 2019 was €338 million ($399M), with 81% of this derived from Vygon’s international business.
Vygon, Value Life
Vygon’s baseline reflects the following philosophy:
- We Value Life through our care and respect for patients
- We Value Life through our development of innovative Medical Devices and their impact in protecting and saving lives
- We Value Life in the broad sense through our environmental commitment and our corporate social responsibility
- We Value Life through providing our employees with a good working environment, our employment practices and careful selection of business partners
- Also our customers/partners Value Life through their career choice so we are aligning our mission with theirs
- Value Life is also a statement encouraging people to “Value Life”